Silviu Sbiera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5397259/publications.pdf

Version: 2024-02-01

73 4,942 31 68
papers citations h-index g-index

75 75 75 5800 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	SOAT1: A Suitable Target for Therapy in High-Grade Astrocytic Glioma?. International Journal of Molecular Sciences, 2022, 23, 3726.	1.8	5
2	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine, 2022, 77, 411-418.	1.1	6
3	Characterization of Adrenal miRNA-Based Dysregulations in Cushing's Syndrome. International Journal of Molecular Sciences, 2022, 23, 7676.	1.8	7
4	Subtype-specific pattern of white blood cell differential in endogenous hypercortisolism. European Journal of Endocrinology, 2022, 187, 439-449.	1.9	7
5	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. Science Advances, 2021, 7, .	4.7	42
6	PKA Cα subunit mutation triggers caspase-dependent RIIβ subunit degradation via Ser <code>¹¹⁴phosphorylation</code> . Science Advances, 2021, 7, .	4.7	4
7	Circulating microRNA Expression in Cushing's Syndrome. Frontiers in Endocrinology, 2021, 12, 620012.	1.5	11
8	Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	1.9	32
9	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. Cancers, 2021, 13, 1736.	1.7	5
10	A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. European Journal of Endocrinology, 2021, 184, 823-835.	1.9	20
11	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	10
12	Case Report: Consecutive Adrenal Cushing's Syndrome and Cushing's Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. Frontiers in Endocrinology, 2021, 12, 731579.	1.5	5
13	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. Cancers, 2021, 13, 4671.	1.7	12
14	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Frontiers in Endocrinology, 2021, 12, 795116.	1.5	2
15	Steroidogenesis in the NCI-H295 Cell Line Model is Strongly Affected By Culture Conditions and Substrain. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 672-680.	0.6	14
16	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.	1.8	24
17	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 219.	1.5	23
18	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma., 2020, 8, e000469.		59

#	Article	IF	Citations
19	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death and Disease, 2020, 11, 192.	2.7	39
20	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers, 2020, 12, 689.	1.7	14
21	Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer. Cancers, 2020, 12, 724.	1.7	16
22	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	1.7	23
23	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2642-2653.	1.8	18
24	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	3.4	57
25	Driver mutations in USP8 wild-type Cushing's disease. Neuro-Oncology, 2019, 21, 1273-1283.	0.6	65
26	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. Clinical Chemistry, 2019, 65, 1276-1286.	1.5	19
27	Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. Endocrinology, 2019, 160, 447-459.	1.4	32
28	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2535-2546.	1.8	29
29	The New Genetic Landscape of Cushing's Disease: Deubiquitinases in the Spotlight. Cancers, 2019, 11, 1761.	1.7	27
30	Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. Molecular and Cellular Endocrinology, 2019, 480, 36-41.	1.6	8
31	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. Endocrinology, 2018, 159, 1511-1524.	1.4	37
32	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. European Journal of Endocrinology, 2018, 178, 181-188.	1.9	15
33	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4511-4523.	1.8	92
34	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
35	Dosage-dependent regulation of <i>VAV2</i> expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. Science Signaling, 2017, 10, .	1.6	35
36	Topoisomerase $2\hat{l}_{\pm}$ and thymidylate synthase expression in adrenocortical cancer. Endocrine-Related Cancer, 2017, 24, 319-327.	1.6	24

#	Article	IF	CITATIONS
37	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. Scientific Reports, 2017, 7, 49.	1.6	17
38	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4323-4332.	1.8	79
39	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	1.8	33
40	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget, 2017, 8, 9323-9338.	0.8	27
41	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	1.8	44
42	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	7.7	482
43	<scp>FATE</scp> 1 antagonizes calcium―and drug―induced apoptosis by uncoupling <scp>ER</scp> and mitochondria. EMBO Reports, 2016, 17, 1264-1280.	2.0	102
44	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. Hormones and Cancer, 2016, 7, 345-355.	4.9	12
45	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	1.8	65
46	The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition. Molecular and Cellular Endocrinology, 2016, 428, 68-81.	1.6	25
47	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. European Journal of Endocrinology, 2016, 174, 343-353.	1.9	20
48	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. European Journal of Endocrinology, 2016, 174, 363-372.	1.9	100
49	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. PLoS ONE, 2016, 11, e0169009.	1.1	7
50	Expression of <scp>LIN</scp> 28 and its regulatory micro <scp>RNA</scp> s in adult adrenocortical cancer. Clinical Endocrinology, 2015, 82, 481-488.	1.2	25
51	The New Molecular Landscape of Cushing's Disease. Trends in Endocrinology and Metabolism, 2015, 26, 573-583.	3.1	26
52	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.	1.6	27
53	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	1.4	153
54	Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. Hormones and Cancer, 2015, 6, 225-236.	4.9	8

#	Article	IF	Citations
55	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nature Genetics, 2015, 47, 31-38.	9.4	450
56	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	1.1	41
57	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. European Journal of Endocrinology, 2014, 171, R1-R11.	1.9	37
58	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	9.4	560
59	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. New England Journal of Medicine, 2014, 370, 1019-1028.	13.9	355
60	Survivin in Adrenocortical Tumors - Pathophysiological Implications and Therapeutic Potential. Hormone and Metabolic Research, 2013, 45, 137-146.	0.7	19
61	Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence?. PLoS ONE, 2013, 8, e73959.	1.1	58
62	Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clinical Cancer Research, 2012, 18, 3452-3461.	3.2	64
63	Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2251-E2260.	1.8	38
64	Single Nucleotide Polymorphism Microarray Analysis in Cortisol-Secreting Adrenocortical Adenomas Identifies New Candidate Genes and Pathways. Neoplasia, 2012, 14, 206-IN13.	2.3	31
65	Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. Frontiers in Endocrinology, 2011, 2, 27.	1.5	29
66	\hat{l}^2 -Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. Clinical Cancer Research, 2011, 17, 328-336.	3.2	128
67	Influence of Short-Term Glucocorticoid Therapy on Regulatory T Cells In Vivo. PLoS ONE, 2011, 6, e24345.	1.1	46
68	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 2010, 23, 1596-1604.	2.9	46
69	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E161-E171.	1.8	196
70	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer, 2009, 16, 907-918.	1.6	63
71	Dendritic Cell Based Immunotherapy - A Promising Therapeutic Approach for Endocrine Malignancies. Hormone and Metabolic Research, 2008, 40, 89-98.	0.7	15
72	Association of Human Polyomavirus JC with Peripheral Blood of Immunoimpaired and Healthy Individuals. Journal of NeuroVirology, 2003, 9, 81-87.	1.0	39

SILVIU SBIERA

#	Article	IF	CITATIONS
73	Association of Human Polyomavirus JC with Peripheral Blood of Immunoimpaired and Healthy Individuals. Journal of NeuroVirology, 2003, 9, 81-87.	1.0	6